Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

ClinicalTrials.gov ID: NCT04784715

Public ClinicalTrials.gov record NCT04784715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

Study identification

NCT ID
NCT04784715
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,157 participants

Conditions and interventions

Interventions

  • Trastuzumab deruxtecan Drug
  • Placebo Drug
  • Taxane Drug
  • Pertuzumab Drug
  • Trastuzumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 25, 2021
Primary completion
Jul 5, 2026
Completion
Dec 29, 2029
Last update posted
May 21, 2026

2021 – 2029

United States locations

U.S. sites
30
U.S. states
19
U.S. cities
28
Facility City State ZIP Site status
Research Site Tucson Arizona 85711
Research Site Springdale Arkansas 72762
Research Site Glendale California 91204
Research Site Glendale California 91206
Research Site Longmont Colorado 80501
Research Site Miami Florida 33176
Research Site Palm Bay Florida 32909
Research Site Plantation Florida 33324
Research Site Atlanta Georgia 30318
Research Site Louisville Kentucky 40241
Research Site Silver Spring Maryland 20904
Research Site Boston Massachusetts 02215
Research Site Detroit Michigan 48202
Research Site Jackson Mississippi 39213
Research Site Las Vegas Nevada 89128
Research Site Summit New Jersey 07901
Research Site New York New York 10065
Research Site Shirley New York 11967
Research Site York Pennsylvania 17403
Research Site Germantown Tennessee 38138
Research Site Dallas Texas 75203
Research Site Dallas Texas 75246
Research Site Denton Texas 76201
Research Site Houston Texas 77090
Research Site San Antonio Texas 78240
Research Site Shenandoah Texas 77380
Research Site Tyler Texas 75702
Research Site Norfolk Virginia 23502
Research Site Roanoke Virginia 24014
Research Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 253 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04784715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 21, 2026 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04784715 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →